GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced that it has appointed Ms. Sue Pierce as Vice President, Product Development, effective April 18, 2011.
Ms. Pierce joins the company with extensive diagnostics experience including over 11 years at Ventana Medical Systems (a division of Roche Diagnostics) and over 14 years at Abbott Laboratories. Most recently, Ms. Pierce was Vice President, Project Management Office in charge of all product development and program management processes across Ventana’s product portfolio. Prior to that she held the role of VP/Sr. Director, Integration and Technical Support, where she developed and led a customer-focused Global Product Technical Support function as well as led the R&D integration activities for the Roche acquisition. She was also previously Director, Product Development where she was responsible for numerous product development and system integration teams, as well as the Design Control team lead for re-engineering and implementation of a new quality system.
While at Abbott Laboratories, Ms. Pierce held roles of increasing responsibility in Abbott’s Diagnostics Division, in Clinical Chemistry, Immunochemistry, and Systems Integration functions. Prior to Abbott Laboratories, she held various R&D and Operations technical positions at Celanese Corporation. Ms. Pierce has a BS in Chemistry and an MS in Analytical Chemistry, both from Oklahoma State University.
"We are very pleased to welcome Sue to the GenMark team," said Chris Gleeson, GenMark's Chairman and CEO. "She brings a wealth of extensive and successful product development experience, a key ingredient at this stage of implementing GenMark’s high growth strategy."About GenMark Diagnostics, Inc. GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark's XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed five diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV